Skip to main content
Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc. — Investor Relations & Filings

Ticker · NVCT ISIN · US67080T1088 US Manufacturing
Open in API
Filings indexed 248 across all filing types
Latest filing 2026-05-05 Interim / Quarterly Rep…
Country US United States of America
Listing US NVCT

About Nuvectis Pharma, Inc.

https://nuvectis.com/

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines and novel targeted therapeutics for the treatment of cancer. The company aims to address serious conditions with unmet medical needs within oncology. Its development pipeline includes the product candidate NXP800.

Recent filings

Filing Released Lang Actions
10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-05 English
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
Earnings Release Classification · 92% confidence The document is a Form 8-K current report under Item 2.02 “Results of Operations and Financial Condition,” which furnishes a press release announcing the company’s first quarter financial results. This aligns with an earnings release—an initial announcement of quarterly financial results. Therefore, it should be classified as ER (Earnings Release). Q1 2026
2026-05-05 English
EFFECT - Nuvectis Pharma, Inc. (0001875558) (Filer)
Regulatory Filings
2026-02-23 English
S-3 Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Nuvectis Pharma, Inc. It is a registration statement under the Securities Act of 1933 for the offering of securities including common stock, preferred stock, warrants, debt securities, and units. The document includes a base prospectus and an at-the-market offering prospectus. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters) and contains detailed offering information, not just an announcement or a brief notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2026-02-13 English
10-K Filing
Annual Report FY 2025
2026-02-11 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02, "Results of Operations and Financial Condition," and states that a press release announcing financial results for the fiscal year ended December 31, 2025, is furnished as an exhibit. The document itself does not contain detailed financial statements or comprehensive financial analysis but rather provides a corporate update and references an attached press release. The length of the document is 3950 characters, which is relatively short and consistent with a current report rather than a full annual or quarterly report. Since the document is a current report announcing financial results and providing a press release, it fits best under the category of Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only.
2026-02-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.